26.4.2017 17:19 | Nasdaq OMX
Taconic Biosciences Expands Microbiome Product and Service Platform
HUDSON, N.Y., April 26, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services and the only commercial provider of germ-free mice, announced that effective April 26, 2017 they will expand their microbiome product and services platform to include custom Fecal Microbiota Transplantation (FMT) services. To support these new FMT services, Taconic will also offer custom germ-free derivations using either client mouse models, Taconic's commercial offerings , or mice sourced from third parties.
This new FMT service offering capitalizes on Taconic's decades of microbiome experience, existing portfolio of germ-free offerings including Germ-Free C57BL/6NTac and Swiss Webster mice, and ability to derive germ-free animals from Taconic's large catalog of mutant mice or client-provided models.
Dr. Alexander Maue, Taconic Biosciences' portfolio director for microbiome products and services, commented, "The germ-free mouse is the ideal substrate to evaluate the properties of complex or defined gut microbiota following FMT. Axenic mice transplanted with donor microbiota can be used to assess the effects of gut bacteria on a wide range of biological systems, including but not limited to, immunity, neurodegenerative diseases, obesity, and diabetes."
"Our custom germ-free derivation services enable Taconic to generate initial cohorts of up to 40 germ-free animals, allowing researchers to generate rapid study cohorts."
Prior to the start of any custom FMT project or germ-free derivation service, Taconic consults with the client to understand their research goals and develop a strategy for project execution. A dedicated Project Manager will keep clients updated throughout the project. Following FMT, Taconic offers a range of husbandry options to accommodate studies of all sizes and durations including options for isolators and state of the art individually ventilated cages (IVCs).
In addition to providing microbiome products and services, Taconic also is a fully-licensed provider of rodent model generation services and has twenty years of model design experience. Complimenting this expertise is Taconic's unique capability of providing a seamless transition from model design to breeding and colony management, thus offering customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.
To learn more about Taconic's microbiome products and services, please contact Taconic Biosciences at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe or at firstname.lastname@example.org .
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Kelly Owen Grover
Director of Marketing Communications
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
Promethean, Inc.18.8.2017 18:40 | pressemeddelelse
Promethean Opens New Global Headquarters in Seattle
Hminers18.8.2017 11:01 | pressemeddelelse
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs
Nasdaq17.8.2017 18:51 | pressemeddelelse
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market
Tetraphase Pharmaceuticals17.8.2017 14:31 | pressemeddelelse
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
RedHill Biopharma Ltd.17.8.2017 13:01 | pressemeddelelse
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
Safway Group16.8.2017 19:41 | pressemeddelelse
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum